• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pediapharm wins Health Canada nod for antibiotic, steroid combo ear drop

December 12, 2016 By Sarah Faulkner

Pediapharm wins Health Canada nod for antibiotic, steroid combo ear dropPediapharm Inc. (CVE:PDP) said today that it won regulatory approval from Health Canada for its Otixal eye drop solution for the treatment of acute otitis media with tympanostomy tubes in pediatric patients.

The Quebec-based company touts Otixal as the 1st antibiotic and steroid combination ear drop available in single, sterile unit-dose packaging. Otitis media, or middle ear inflammation, is 1 of the most common pediatric infections in Canada, according to Pediapharm. Tympanostomy tubes can be inserted in the eardrum to drain fluid from the middle ear in children with recurrent acute otitis media.

“The most common symptom of AOMT for many children is fluid drainage from the ear (otorrhea) and having a new medication to treat those children is more than welcome,” Dr. Peter Spafford, president of the Canadian Society of Otolaryngology – Head & Neck Surgery, explained. “Additionally, delivering drops into children’s ears is not always easy for parents. Otixal’s unique single-use, premeasured dosing helps assure an accurate dose every time. This will certainly help parents to be more compliant with the medication.”

“Otixal represents a great opportunity to introduce innovation in a growing market that has not seen innovation for years” Pediapharm’s VP of sales & marketing Richard Labelle said in prepared remarks. “Given its strong medical evidence and unique delivery mode, Otixal has the potential to significantly improve the quality of life of many young patients who have undergone tympanostomy tube insertion and are suffering from acute otitis media”

“We are very pleased with the approval of Otixal, which represents the 2nd Health Canada approval within six months for us” president & CEO Sylvain Chretien added. “With our strong infrastructure in place and with our track record in successfully launching drugs, we are very confident in our ability to make Otixal a success in Canada.”

Filed Under: Featured, Otolaryngology Ear, Nose & Throat, Pediatrics, Regulatory/Compliance Tagged With: Pediapharm

IN CASE YOU MISSED IT

  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS